Resolve Therapeutics, a biotechnology company involved in first-in-class, targeted, safe therapies for underserved autoimmune diseases, announced on Wednesday that it has completed enrolment for the company's phase two clinical trial of RSLV-132 in patients with long covid.

The company has enrolled 113 participants for the study.

The primary endpoint of the study is to evaluate an improvement in patient fatigue utilising the PROMIS SF 7a instrument. The last subject will complete the study in January and top-line data will be revealed in the first quarter of 2023.